Asthma and COPD Management

Initial Therapy and Treatment Options

• For patients with persistent symptoms despite initial therapy, increasing the bronchodilator dose, adding a second long-acting bronchodilator, or considering the addition of an inhaled corticosteroid (ICS) for frequent exacerbators is recommended by the European Respiratory Society 1
• Progressing to a long-acting bronchodilator (LABA or LAMA) is recommended for patients with persistent symptoms, with a preference for LAMA due to its superior effect on exacerbation reduction, and considering LAMA+LABA combination if symptoms persist, as suggested by the American Thoracic Society 2, 3
• The following therapy is recommended based on symptoms and exacerbation risk:

• Triple therapy, consisting of LAMA/LABA/ICS, is recommended for patients with persistent symptoms and frequent exacerbations, and ICS/LABA combinations for patients with a history of exacerbations, as recommended by the American Thoracic Society and the Global Initiative for Chronic Obstructive Lung Disease 2
• Roflumilast (PDE4 inhibitor) may be considered for patients with severe disease and chronic bronchitis, and a history of exacerbations, and a macrolide for frequent exacerbators despite optimal therapy, while being aware of the risk of bacterial resistance, as suggested by the American Thoracic Society 2

Prevention and Lifestyle Modifications

• Vaccinations, including annual influenza vaccine and pneumococcal vaccines, are recommended for all COPD patients, as well as providing nutritional support for malnourished patients, and addressing weight loss and malnutrition with smaller, more frequent meals to reduce dyspnea from abdominal bloating, as recommended by the American Thoracic Society 2, 6, 7
• Smoking cessation is the most important intervention to slow disease progression, with options including nicotine replacement therapy, varenicline, bupropion, and combined behavioral support, as emphasized by the American College of Chest Physicians 2
• Pulmonary rehabilitation, a multimodality program including exercise training, education, and behavioral intervention, is strongly recommended for COPD patients, improving endurance, reducing dyspnea, and reducing hospitalizations, particularly beneficial for emphysema patients, as recommended by the American Thoracic Society 2, 6, 8, 9, 7

Mental Health and Comorbidities

• Anxiety and depression should be addressed with treatment options including selective serotonin reuptake inhibitors, short-acting benzodiazepines, buspirone, and non-pharmacologic relaxation techniques, as recommended by the American Thoracic Society 6
• Screening for alpha-1 antitrypsin deficiency is recommended, especially in younger patients or those with minimal smoking history, and alpha-1 antitrypsin augmentation therapy should be considered for patients with severe hereditary alpha-1 antitrypsin deficiency and established emphysema, as recommended by the American Thoracic Society and the European Respiratory Society 2, 6

Oxygen Therapy and Monitoring

• Oxygen therapy is indicated for stable patients with severely low oxygen levels, or those with evidence of pulmonary hypertension, peripheral edema, or polycythemia, with a target oxygen saturation of 88-92% for patients with respiratory acidosis or at risk of hypercapnic respiratory failure, as recommended by the American Thoracic Society and the European Respiratory Society, with a strength of evidence rated as high 2, 10, 11
• Regular assessment of symptoms, exacerbation frequency, lung function, exercise capacity, oxygen saturation, and inhaler technique is recommended, with adjustments to therapy based on response and disease progression, as suggested by the Canadian Thoracic Society and GOLD 5, 2

Patient Education and Inhaler Technique

• Provide basic information about COPD, proper medication use, and strategies to minimize dyspnea, as suggested by the American College of Chest Physicians, and ensure patient preference and ability to use the delivery device guides selection, with regular reassessment of inhaler technique at every visit 2, 3, 9
• The European Respiratory Society advises against the use of beta-blockers, including eye drops, as they can worsen symptoms, and the American College of Chest Physicians and British Thoracic Society advise against using inhaled corticosteroid (ICS) monotherapy in COPD, and the American Thoracic Society notes that regular use of ICS increases the risk of pneumonia, especially in patients with severe disease 9, 12, 2